公开(公告)号：US20230190964A1

公开(公告)日：2023-06-22

申请号：US18045650

申请日：2022-10-11

Applicant: 4D MOLECULAR THERAPEUTICS INC.

Inventor： David H. Kirn ,  Melissa Kotterman ,  Peter Francis ,  David Schaffer ,  Paul Szymanski ,  Kevin Whittlesey

IPC: A61K48/00 ,  A61P3/00

CPC classification number: A61K48/0066 ,  A61P3/00 ,  A61K48/0083 ,  A61K48/0075

Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.

公开(公告)号：US11802278B2

公开(公告)日：2023-10-31

申请号：US18045650

申请日：2022-10-11

Applicant: 4D MOLECULAR THERAPEUTICS INC.

Inventor： David H. Kirn ,  Melissa Kotterman ,  Peter Francis ,  David Schaffer ,  Paul Szymanski ,  Kevin Whittlesey

IPC: C12N9/40 ,  A61K9/00 ,  A61P3/00 ,  C12N15/86 ,  A61K48/00

CPC classification number: C12N9/2465 ,  A61K9/0019 ,  A61K48/0066 ,  A61K48/0075 ,  A61K48/0083 ,  A61P3/00 ,  C12N15/86 ,  C12Y302/01022 ,  A61K48/00 ,  C12N2840/00

Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.

公开(公告)号：US11198858B2

公开(公告)日：2021-12-14

申请号：US17240948

申请日：2021-04-26

Applicant: 4D MOLECULAR THERAPEUTICS INC.

Inventor： David H. Kirn ,  Melissa Kotterman ,  Peter Francis ,  David Schaffer ,  Paul Szymanski ,  Kevin Whittlesey

IPC: C12N9/40 ,  A61K9/00 ,  A61P3/00 ,  C12N15/86 ,  A61K48/00

Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.